Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Neal Flomenberg Sells 1,078,600 Shares

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) insider Neal Flomenberg sold 1,078,600 shares of the stock in a transaction that occurred on Thursday, October 17th. The shares were sold at an average price of $1.62, for a total value of $1,747,332.00. Following the completion of the sale, the insider now directly owns 4,254,302 shares of the company’s stock, valued at approximately $6,891,969.24. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Tevogen Bio Stock Up 54.0 %

Shares of TVGN stock opened at $2.48 on Thursday. The firm’s 50-day moving average is $0.63 and its two-hundred day moving average is $0.86. Tevogen Bio Holdings Inc. has a 12 month low of $0.26 and a 12 month high of $21.09.

Institutional Trading of Tevogen Bio

An institutional investor recently bought a new position in Tevogen Bio stock. Portland Global Advisors LLC bought a new position in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,782,209 shares of the company’s stock, valued at approximately $21,683,000. Tevogen Bio comprises about 3.0% of Portland Global Advisors LLC’s portfolio, making the stock its 9th biggest holding. Portland Global Advisors LLC owned about 36.55% of Tevogen Bio at the end of the most recent quarter.

Analysts Set New Price Targets

Separately, Fundamental Research set a $4.20 target price on Tevogen Bio and gave the stock a “buy” rating in a research note on Friday, June 28th.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.